• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

iPLEDGE and the AAD: What Happens Now?


Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/SGM Expert Resource Group, sits down with Dermatology Times® to discuss what changes were made to the iPLEDGE platform, examples of how the roll out has been unsuccessful, and how patients should be wary of trying to take old medications.

There is an emergency meeting happening today between the American Academy of Dermatology (AAD) and key experts in this situation to help come to a solution. Below is the AAD's announcement:

"AADA to meet with leaders of HHS, FDA, and Syneos Health

Due to the Academy’s tireless outreach regarding the unacceptable situation with iPLEDGE, the FDA has convened an emergency meeting with AADA representatives and Admiral Rachel L. Levine, MD, assistant secretary for health; Patrizia Cavazzoni, MD, director of the FDA Center for Drug Evaluation and Research; and the CEO of Syneos Health, the iPLEDGE administrator, on Thursday, Dec. 16.

The Academy also received an update yesterday from representatives with Syneos Health, who acknowledged the AADA’s concerns and reported they are actively working with their service providers to resolve website issues, hold times, and access to the call center, although a timeline was not provided.

At the Thursday meeting, AADA representatives will underscore the urgent situation faced by dermatology patients unable to secure their prescriptions, repeat calls for a halt to the program so that care can be restored without further delay and disruption, and outline plans for how dermatologists will maintain patient safety while the program is suspended.

AADA is encouraging members to continue to share experiences leading up to the Thursday meeting with the FDA via our grassroots Take Action Center."

Related Videos
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
© 2024 MJH Life Sciences

All rights reserved.